Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

SPD 557

Drug Profile

SPD 557

Alternative Names: M-0003; SHP-557; SPD-557; SSP-002358

Latest Information Update: 16 Jan 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Janssen Pharmaceutica; Ortho-McNeil Pharmaceutical
  • Developer Movetis; Shire-Movetis NV
  • Class Gastrokinetics
  • Mechanism of Action Serotonin 4 receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Diabetic gastroparesis; Gastro-oesophageal reflux; Gastroparesis

Most Recent Events

  • 08 Jan 2019 Shire has been acquired and merged into Takeda
  • 30 Jun 2013 Discontinued - Phase-II for Gastro-oesophageal reflux in Belgium (PO)
  • 30 Jun 2013 Discontinued - Phase-II for Gastro-oesophageal reflux in Czech Republic (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top